45例腮腺腺样囊性癌临床分析

４５例腮腺腺样囊性癌临床分析孟刚马东白袁建达关键词腮腺腺样囊性癌治疗作者单位：上海医科大学附属肿瘤医院（上海２０００３２）腮腺腺样囊性癌为具有特殊生物学行为的涎腺恶性肿瘤，临床表现特殊，病理形态复杂，本文对４５例分析讨论如下。临床资料一般资料１９５５...     

90例腮腺腺样囊性癌的临床分析

目的总结腮腺腺样囊性癌的疗效.方法本组90例手术治疗30例,综合治疗60例.其中术后化疗30例,术后放疗80例.手术、化疗、放疗综合治疗.结果随访1～10年,3年生存率为100%,5年生存率为90%,10年生存率为60%.结论综合治疗是治疗腮腺腺样囊性癌的根本方法.     

31例复发性腮腺腺样囊性癌临床分析

目的探讨腮腺腺样囊性癌诊断及复发癌治疗方法。方法对31例复发性腮腺腺样囊性癌作临床分析。结果局部切除或浅叶切除复发时间比全腮腺切除复发时间短。复发后采用手术＋放疗比单纯手术的疗效好。颈淋巴结转移率低，本组为10.3％（3／29）。结论B超、CT及肿瘤穿刺细胞学检查有助术前诊断。全腮腺切除应视为常规，术后复发可采用扩大切除术，但应补充放疗。预防性颈淋巴结清除术不应视为常规。     

头颈部腺样囊性癌的治疗进展

腺样囊性癌是涎腺常见的恶性肿瘤之一。目前,对于腺样囊性癌的标准治疗是手术为主和术后辅助放射治疗,化疗和分子靶向治疗对于腺样囊性癌治疗效果尚未肯定,文章主要介绍有关头颈部腺样囊性癌治疗的进展。     

双侧腮腺腺样囊性癌1例并文献复习

腺样囊性癌(adenoid cystic carcinoma,ACC)多发生于颌面部大、小涎腺,其中腭部最为常见,现有文献中腮腺ACC双侧发病率极低,仅有1973年法国报道1例.1 病例资料患者,女性,65岁,2013年7月因左耳后肿物8年余,发现右咽旁肿物半月入本院.无进食肿胀,无耳鸣、听力下降,无闭眼不全、口角歪斜.否认系统性疾病史、家族性疾病史及肿瘤性疾病史.查体见左乳突前下缘可及大小分别为1.0 cm ×1.0 cm、1.5 cm×1.7cm、2.0 cm ×2.0 cm的3个肿物,轻压痛、活动度尚可、界尚清、质地中等.右腮腺区未及明显肿块,咽腔右侧略饱满,软腭活动可,扁桃体无肿大.无面瘫症状,无声嘶.     

31例复发性腮腺腺样囊性癌临床分析

目的探讨腮腺腺样囊性癌诊断及复发癌治疗方法。方法对31例复发性腮腺腺样囊性癌作临床分析。结果局部切除或浅叶切除复发时间比全腮腺切除复发时间短。复发后采用手术 放疗比单纯手术的疗效好。颈淋巴结转移率低,本组为10.3%(3/29)。结论B超、CT及肿瘤穿刺细胞学检查有助术前诊断。全腮腺切除应视为常规,术后复发可采用扩大切除术,但应补充放疗。预防性颈淋巴结清除术不应视为常规。     

支气管腺样囊性癌的诊断与治疗体会

探讨支气管腺样囊性癌的临床特点，病理特征和治疗原则，总结12例支气管腺样囊性癌的治疗经验，3年生存率100%（12/12），5年生存率75%（9/12），支气管腺样囊性癌是一种少见的低度恶性肿瘤，手术切除是最有效的治疗方法。     

晚期转移性头颈部腺样囊性癌治疗进展

晚期转移性腺样囊性癌目前无标准的治疗方案,各个指南现在对头颈部腺样囊性癌的治疗规范较少,关于晚期转移性腺样囊性癌的治疗以全身治疗为主,化疗方案多采用以蒽环类和环磷酰胺为主的联合治疗方案,紫杉类和吉西他滨治疗无效,部分靶向药物治疗有效,但是有效率均不超过20％.我们总结现有的数据,为晚期转移性腺样囊性癌的治疗提供循证医学...     

乳腺腺样囊性癌

乳腺腺样囊性癌张保宁胡兴胜李泰生刘复生高峰刘宁乳腺腺样囊性癌（ａｄｅｎｏｉｄｃｙｓｔｉｃｃａｒｃｉｎｏｍａ，ＡＣＣ），又名乳腺腺囊癌或圆柱瘤，是浸润性乳腺癌的特殊类型，临床少见。我院外科２８年仅收治４例，现报告如下。临床资料本组男１例，女３例。年龄...     

头颈部腺样囊性癌的放射治疗

1971年3月～1986年8月收治51例头颈部腺样囊性癌。其中单纯放疗9例,术后复发再放疗14例,术后补充放疗16例,术前放疗4例,单纯手术8例。照射剂量30～80Gy/3～8周。5年、10年和15年生存率分别是51.0％(26/51)、40.9％(9/22)和36.4％(4/11),5年、10年和15年无病生存率分别是39.2％(20/51)、31.8％(7/22)和36.4％(4/11)。单纯放疗及术后复发再放疗共23例中放疗后完全消退3例,消退≥50％10例,消退<50％10例,年生存率为47.8％(11/23),有较好的姑息作用。术后补充放疗5年生存率68.7％(11/16),疗效肯定应予提倡。单纯放疗剂量应70～80Gy/7～8周甚至更高。颈部淋巴结不做预防照射后转移率10.3％(3/29)。不主张预防照射颈部。     

Multiple brain metastases: a rare manifestation of adenoid cystic carcinoma of the parotid gland

A rare case of multiple hematogenous brain metastases from adenoid cystic carcinoma of the parotid gland is reported. The patient had a parotid tumor that was treated ten years prior to the appearance of the brain metastases. Magnetic resonance imaging (MRI) and histological findings, as well as the radiation therapy response, of this tumor are presented.     

Adenoid cystic carcinoma of Bartholin's gland: review of the literature and report of two cases

Two patients with adenoid cystic carcinoma of Bartholin's gland and a review of the relevant literature are presented. With the inclusion of these two patients, there are now 24 cases reported. Both patients had large vulvar masses with a short clinical history, and several local tumor recurrences within the first 21/2 years after radical vulvectomy. The characteristic cribriform pattern and perineural involvement in addition to vascular invasion were present in the pathological material. No metastases were found in the inguino-femoral lymph nodes removed. Both patients are alive, without evidence of local recurrence but with lung metastases. A chemotherapeutic treatment scheme (adriamycin and cyclophosphamide) is underway but it is too early to evaluate its results.     

Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma

Background

Pim-1 (Provirus integration site for Moloney murine leukemia virus 1) belongs to the Ser/Thr kinase family and plays a pivotal role in occurrence and development of oncogenesis. Recent studies have demonstrated that Pim-1 phosphorylates RUNX3 and alters its subcellular localization. However, few studies have concerned the implications of Pim-1 in the salivary gland adenoid cystic carcinoma (ACC). In this study, we aimed to clarify the function of Pim-1 in ACC in vitro. Meanwhile, we measured the levels of Pim-1 and RUNX3 in the ACC tissues. The correlations between Pim-1/RUNX3 levels and clinical parameters were also analyzed.

Methods

SACC-83 and SACC-LM cells were transfected with the Pim-1 siRNA. Pim-1 mRNA and protein expression were measured using real-time PCR and immnuoblot, respectively. Cell proliferation was analyzed by CCK-8 assay. Cell cycle, apoptosis, and mitochondrial membrane potential were detected by flow cytometry. Effects of Pim-1 on cells’ invasion were evaluated by transwell migration assay. Pim-1 and RUNX3 levels in ACC tissues were examined by immunohistochemistry.

Results

Pim-1 siRNA reduces cell proliferation, induces apoptosis, causes cell cycle arrest through cell cycle related proteins (Cyclin D1 and CDK4), mitochondrial depolarization, and decreases invasive ability in SACC-83 and SACC-LM cells. Pim-1 and RUNX3 levels are significantly relevant and associated with T-stage and nerve invasion in the ACC tissues.

Conclusions

This study demonstrates the oncogenic role of Pim-1 in ACC. The findings also suggest that Pim-1 may serve as a neoteric therapeutic target and potential prognostic marker for ACC cancer.

     

Estrogen receptor expression in salivary gland mucoepidermoid carcinoma and adenoid cystic carcinoma

Estrogen receptor (ER) expression in salivary gland carcinomas is controversial, and most published studies considered no more than 10 cases. We analyzed ER expression by immunohistochemistry in 136 mucoepidermoid carcinomas and 72 adenoid cystic carcinomas. All cases were negative. These results do not support a role for estrogens in salivary gland mucoepidermoid carcinoma and adenoid cystic carcinoma.     

唾液腺腺样囊性癌颈淋巴结转移规律的临床研究*

目的:本研究旨在回顾性分析头颈部腺样囊性癌的颈部淋巴结的临床转移规律。方法:回顾性分析1995年1 月至2008年12月就诊于上海交通大学医学院附属第九人民医院口腔颌面- 头颈肿瘤科的616 例腺样囊性癌患者的临床资料,对其中62例腺样囊性癌合并颈部淋巴结转移的患者进行临床统计学分析。结果:头颈部腺样囊性癌的颈淋巴结转移的发生率约为10% ,原发于舌根、舌体及口底部的腺样囊性癌较其他部位更易发生颈部淋巴结转移,分别为19.2% 、17.6% 和15.3% ,转移部位多发生在Ⅰb区与Ⅱ区。淋巴结转移的方式以经典的管道性转移为主,直接浸润型转移仅常见于下颌下腺的腺样囊性癌累及颌下淋巴结。原发部位及瘤周淋巴血管浸润与颈部淋巴结转移的发生密切相关。出现颈部淋巴结转移的患者其临床预后明显较差（P < 0.01）。结论:舌- 口底复合体为头颈部腺样囊性癌发生淋巴结转移的常见原发部位,在临床治疗及随访上应得到更多关注。      

Ezrin在涎腺腺样囊性癌组织中的表达

目的:探讨Ezrin在涎腺腺样囊性癌组织中的表达及意义。方法:用免疫组织化学SP法检测Ezrin在涎腺腺样囊性癌组织和正常涎腺组织中的表达,分析其在涎腺腺样囊性癌组织中的表达与肿瘤的侵袭性、复发、转移和预后的关系。结果:Ezrin在涎腺腺样囊性癌和正常涎腺组织中的阳性率表达分别为44.68%和9.09%,P<0.05;在癌细胞中主要为胞质内表达,染色深,而在正常涎腺组织则主要为细胞膜表达,染色浅或阴性。Ezrin的表达强度与有无神经受侵、有无发生局部复发及远处转移相关,P<0.05。Ezrin表达阳性组和阴性组的5年累积生存率分别为66.70%和100.00%,10年累及生存率分别为27.83%和95.00%,阳性组较阴性组预后差,P<0.05。结论:Ezrin的表达强度与涎腺腺样囊性癌的发生、侵袭性、复发和转移性有关,且Ezrin阳性表达预示患者预后不良。     

腮腺分泌性癌临床病理分析（附2例）

目的:探讨分泌性癌（secretory carcinoma,SC）的分子遗传学特点、病理诊断与鉴别诊断特征、治疗及预后。方法:对2例罕见的腮腺SC进行组织形态分析及免疫组化研究,并复习相关文献。结果:男性患者2例,年龄分别为37岁和45岁,均因发现左面部无痛渐大肿物数年入院,CT均提示左侧腮腺占位。镜下见肿瘤细胞小到中等大,胞核呈圆形及卵圆形,可见小核仁,胞浆丰富,呈嗜酸性颗粒状。这些瘤细胞排列成实性、腺管状、微囊/筛状、乳头状-囊性等结构,周围包绕纤维间隔,部分腔隙内含有胶状或黏液样分泌物,偶见病理性核分裂象,未见坏死。免疫组化显示肿瘤细胞弥漫且强烈地表达Mammaglobin、S-100和SOX10,弥漫表达CK7、CK18、CD117和Vimentin,不同程度地表达GATA3,DOG1大部分区域表达缺失,仅在少数瘤巢周或腔缘呈弱阳性,而CgA、Syn、p63、GCDFP-15、AR和HER-2均阴性,Ki-67增殖指数约10%。结论:通常SC是一种罕见的低度恶性肿瘤,凭借对组织形态特征与免疫组化检测结果的仔细分析,大多数情况下足以做出SC的病理学诊断而勿须分子检测。     

74例原发性气管腺样囊性癌的临床分析

目的探讨原发性气管腺样囊性癌的临床特点。方法74例患者均经病理或细胞学证实。T分期中T18例（10.8%）,T219例（25.7%）,T323例（31.1%）,T424例（32.4%）。纵隔淋巴结阳性8例（10.8%）。远处转移2例（2.7%）。62例（83.8%）接受手术治疗,27例手术完全切除,R1或R2切除35例。单纯手术24例,单纯放疗12例,综合治疗38例。结果复发或转移的患者共43例（58.1%）,局部复发20例,远处转移17例,局部复发＋远处转移6例。除2例外,所有远处转移患者均有肺转移。第一次复发或转移的中位时间为32月,第二次、第三次复发或转移的中位时间分别为12月和6月。所有患者中位生存时间55月,5年、10年总生存率分别为69.7%和35.9%。结论原发性气管腺样囊性癌治疗效果较好。病变长度、T分期以及包含手术的治疗可能是影响预后的因素。患者治疗后出现多次复发或转移,积极治疗仍能获得长期生存的机会。远处转移中肺转移最多见。     

Primary adenoid cystic carcinoma of the lung: absence of KIT mutations

BACKGROUND: Primary pulmonary adenoid cystic carcinomas (ACCs) are rare lung neoplasms that are challenging to completely resect and can exhibit poor survival. Adjuvant therapy is often ineffective and identification of a targeted novel therapy would be useful. The objective of the current study was to evaluate KIT expression and KIT-activating mutations. METHODS: Primary salivary gland-type tumors of the lung diagnosed between 1972 and 2002 at the Mayo Clinic were identified and the subset of primary pulmonary ACCs were reviewed. Immunohistochemical study for KIT expression and KIT gene mutations in exons 9, 11, 13, and 17 were performed on paraffin-embedded tissue. RESULTS: Forty-nine patients were diagnosed with primary pulmonary ACC. The majority of ACC cases were predominantly the cribriform type (74.4%). KIT immunoreactivity was evaluated in 34 cases and was found to be present in all but 1 case (97%). No mutations were detected in KIT gene exons 9, 11, 13, and 17 in a subset of 12 cases. CONCLUSIONS: Although KIT expression was found frequently in primary pulmonary ACC, a correlation with KIT-activating mutations was not observed.